Navigation Links
Two designer drugs hit same lung cancer target, but only one is effective

Two designer cancer drugs differed dramatically in a laboratory test comparing their ability to shut down a mutant, overactive growth signal in lung cancer cells, reports a team headed by scientists at the Dana-Farber Cancer Institute.

Although both drugs killed cells containing a normal but overactive EGFR (epidermal growth factor receptor) molecule, only gefitinib (Iressa) killed lung cancer cells containing a mutated EGFR molecule. The monoclonal antibody drug cetuximab (Erbitux) had little effect on the mutant signal, evidently because it strikes at a different part of the EGFR molecule.

Reporting in the Aug. 17 issue of the Journal of the National Cancer Institute, the researchers say that the divergent results add to growing evidence that mutations in the targets of designer drugs critically influence their effectiveness. Erbitux is an effective inhibitor of EGFR signals in colorectal cancer, which involves a normal, not mutant, EGFR molecule.

"We now know of several groups of patients who benefit from therapy targeted at EGFR," says Pasi A. Janne, MD, PhD, of Dana-Farber, and a senior author of the paper. "Those with EGFR mutations will benefit from Iressa or Tarceva (erlotinib), while another group, without EGFR mutations, will benefit from Erbitux."

The lead author is Toru Mukohara, MD, and the senior authors are Bruce E. Johnson, MD, and Jänne, all of Dana-Farber.

Iressa and Erbitux both are designed to squelch the overexpressed, or overactive, EGFR signal that spurs growth in several types of cancer. In some forms of the disease, including lung cancer of the non-small-cell type, and colorectal cancer, the abnormal signals are generated by a normal EGFR molecule. In a small percentage of patients with non-small-cell lung cancer (NSCLC), the overactivity stems from a mutant EGFR protein: those patients tend to have a better outlook, and Iressa and Tarceva are particularly effective for them.

Mukohara and his co
'"/>

Source:Dana-Farber Cancer Institute


Page: 1 2

Related biology news :

1. Mouse with designer liver has enhanced glucose tolerance, insulin response
2. Molecular machine may lead to new drugs to combat human diseases
3. Researchers identify target for cancer drugs
4. MetaChip provides quick, efficient toxicity screening of potential drugs
5. Newly discovered pathway might help in design of cancer drugs
6. UNC launches study of liver injury caused by drugs
7. Findings have implications for tracking disease, drugs at the molecular level
8. Future diabetes drugs may target new protein interaction
9. UCLA study assesses cost-effectiveness of Hepatitis B drugs
10. Sponges as drugs
11. Newest HIV drugs should be used with FUZEON(R)
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Two designer drugs hit same lung cancer target but only one effective

(Date:7/21/2014)... areas across Riau province on Sunday, July 20, indicating ... decline in rainfall. The number of detected hotspots ... been reported one day prior, which had reached only ... regencies and municipalities, most of which were in northern ... creates could potentially spread via winds to Malaysia and ...
(Date:7/21/2014)... CHAMPAIGN, Ill. A new study in mice reveals ... muscle after resistance exercise. , By injecting MSCs ... eccentric exercise (similar to the lengthening contractions performed during ... damage), researchers were able to increase the rate of ... muscles in the exercising mice. , The findings, ...
(Date:7/21/2014)... yourself full of high-fat foods cause you to lose ... Florida State University neuroscientists says so, and it has ... could impact a whole range of human functions that ... obesity. , "This opens up a lot of possibilities ... Nicolas Thiebaud, who led the study examining how high-fat ...
Breaking Biology News(10 mins):Stem cells aid muscle repair and strengthening after resistance exercise 2New research links bad diet to loss of smell 2
... trillions of cells, all derived from a single cell, or zygote, ... single cell contains all the genetic information needed to develop into ... new cell as it divides into the many diverse types of ... If each cell is genetically identical, however, how does ...
... make sure their children drink milk and eat other calcium-rich foods ... make sure their kids eat salmon, almonds and other foods high ... in bone health, according to a study to be presented Sunday, ... Washington, DC. "Lots of nutrients are key for children ...
... and/or improve the quality of life for many cancer patients. ... inducing damage to DNA. The public has an opportunity ... used anticancer drugs and how laboratory research may lead to ... Yinsheng Wang , a professor of chemistry at ...
Cached Biology News:Divide and define: Clues to understanding how stem cells produce different kinds of cells 2Divide and define: Clues to understanding how stem cells produce different kinds of cells 3Magnesium may be as important to kids' bone health as calcium 2How do anticancer drugs work? 2How do anticancer drugs work? 3
(Date:7/21/2014)... (July 21, 2014) The yield so far is ... developed a low-energy, solution-based mineral substitution process to make ... use in electronics and alternative energy devices. , A ... of the July 21 issue of the journal ... research in the inorganic and nuclear chemistry fields. The ...
(Date:7/20/2014)... fuel gets recycled, the process releases radioactive krypton and ... with the related gas radon. A new porous material ... July 20 in Nature Materials shows how: ... not out. , The CC3 material could be ... nuclear fuel or air in buildings and also in ...
(Date:7/18/2014)... , July 18, 2014  Neogen Corporation (Nasdaq: ... Snyder , Neogen,s chief operating officer and president, has ... will work as a consultant going forward on special ... Snyder has been in this position since September 2013. ... by James Herbert , who has been Neogen,s ...
(Date:7/18/2014)... , July 18, 2014  Neurotrope, Inc. (OTCQB: ... Board of Directors appointed Co-Chairmen Charles S. Ramat ... Officers on an interim basis, effective immediately. Messrs. Ramat ... is no longer Chief Executive Officer of Neurotrope Bioscience, ... Company and whose employment agreement with Neurotrope Bioscience Inc. ...
Breaking Biology Technology:Oregon chemists eye improved thin films with metal substitution 2A noble gas cage 2A noble gas cage 3Neurotrope Board of Directors Appoints Chairmen Ramat and Freiman as Interim Co-CEOs 2Neurotrope Board of Directors Appoints Chairmen Ramat and Freiman as Interim Co-CEOs 3Neurotrope Board of Directors Appoints Chairmen Ramat and Freiman as Interim Co-CEOs 4
... AVIV, Israel, October 15 ,Simbionix USA Corporation is ... round of growth capital financing led by River ... Partners and other existing,shareholders, as well as Western ... The investment will enable Simbionix to,accelerate the already ...
... PURE Bioscience (Nasdaq:,PURE), creators of the patented ... the fiscal year ended July 31, 2008 of,$1,487,500, ... in the,prior fiscal year. The Company reported a ... per share, compared with a loss of,$(4,654,900), or ...
... Calif., Oct. 15 SuperGen, Inc.,(Nasdaq: SUPG ... and,development of novel cancer therapies, today announced the ... EORTC-NCI-AACR Symposium on "Molecular,Targets and Cancer Therapeutics" on ... will review clinical and non-clinical advances,in the following ...
Cached Biology Technology:Simbionix Raises Largest Amount in Company's History in Venture Capital to Accelerate Growth 2Simbionix Raises Largest Amount in Company's History in Venture Capital to Accelerate Growth 3PURE Bioscience Reports Fourth Quarter and Year End Results 2PURE Bioscience Reports Fourth Quarter and Year End Results 3PURE Bioscience Reports Fourth Quarter and Year End Results 4PURE Bioscience Reports Fourth Quarter and Year End Results 5PURE Bioscience Reports Fourth Quarter and Year End Results 6PURE Bioscience Reports Fourth Quarter and Year End Results 7SuperGen to Present Data at EORTC-NCI-AACR 2
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
... Immunogen: Recombinant human IDO (Indoleamine-pyrrol ... the ~44 kDa human IDO ... control: IFN-Gamma-stimmulated Human peripheral blood ... reactivity with mouse and rat ...
...
Anti-ZFP-38/RU49 Family: Zinc Finger Peptide Sequence: SVKVEDKDFPSTCSKK...
Biology Products: